Skip to main content
H.R. 5160 119th Congress House

Stem Cell Therapeutic and Research Reauthorization Act of 2025

Official title: To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Introduced: September 4, 2025 Introduced by: Christopher H. Smith Republican · New Jersey See on congress.gov
Health Biological and life sciencesBlood and blood diseasesCell biology and embryologyHealth programs administration and fundingOrgan and tissue donation and transplantation
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 16 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 21, 2026
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Jul 20, 2026 · 3:20 PM EDT
Motion to reconsider laid on the table Agreed to without objection.
Jul 20, 2026 · 3:20 PM EDT
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
Jul 20, 2026 · 3:20 PM EDT
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
Jul 20, 2026 · 3:09 PM EDT
DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
Jul 20, 2026 · 3:09 PM EDT
Considered under suspension of the rules. (consideration: CR H4642-4643)
Jul 20, 2026 · 3:09 PM EDT
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
Jul 2, 2026
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Jul 2, 2026
Placed on the Union Calendar, Calendar No. 629.
May 21, 2026
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
May 21, 2026
Committee Consideration and Mark-up Session Held
May 13, 2026
Subcommittee Consideration and Mark-up Session Held
May 13, 2026
Forwarded by Subcommittee to Full Committee by Voice Vote.
Sep 4, 2025
Referred to the Subcommittee on Health.
Sep 4, 2025
Introduced in House
Sep 4, 2025
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now July 21, 2026

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

 Plain-English summary Congressional Research Service

Stem Cell Therapeutic and Research Reauthorization Act of 2025

This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).

The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.

Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

 Hearings & markups 1
 Related & companion bills 1
  • S 4109 Stem Cell Therapeutic and Research Reauthorization Act of 2026
 Bill text 4 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 25

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 25 filings →
 Cosponsors 21
All 21 Democratic 11 Republican 10
D
Davids, Sharice
Kansas · May 29, 2026
 R
Fitzpatrick, Brian K.
Pennsylvania · May 29, 2026
 R
Lawler, Michael
New York · May 21, 2026
 D
Vindman, Eugene Simon
Virginia · May 21, 2026
 R
Finstad, Brad
Minnesota · Apr 30, 2026
 D
Morrison, Kelly
Minnesota · Apr 30, 2026
 D
Barragán, Nanette Diaz
California · Apr 27, 2026
 R
Bentz, Cliff
Oregon · Apr 27, 2026
 D
Castor, Kathy
Florida · Apr 2, 2026
 R
Garbarino, Andrew R.
New York · Apr 2, 2026
 R
Malliotakis, Nicole
New York · Apr 2, 2026
 D
Norton, Eleanor Holmes
District of Columbia · Apr 2, 2026
 R
Aderholt, Robert B.
Alabama · Feb 10, 2026
 D
Gottheimer, Josh
New Jersey · Feb 10, 2026
 D
Dingell, Debbie
Michigan · Feb 4, 2026
 R
Fischbach, Michelle
Minnesota · Feb 4, 2026
 R
Bilirakis, Gus M.
Florida · Sep 4, 2025
 D
Matsui, Doris O.
California · Sep 4, 2025
 D
Mfume, Kweisi
Maryland · Sep 4, 2025
 D
Pingree, Chellie
Maine · Sep 4, 2025
 R
Tenney, Claudia
New York · Sep 4, 2025
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-HR-5160/
MLA
"H.R. 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-5160/.
Bluebook (legal)
H.R. 5160, 119th Cong. (2026), https://openamerica.io/bill/119-HR-5160/.
Markdown link
[H.R. 5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025](https://openamerica.io/bill/119-HR-5160/)
Report a problem